275 related articles for article (PubMed ID: 18702458)
21. Anticancer activity of hydrogen-bond-stabilized half-sandwich Ru(II) complexes with heterocycles.
Mitra R; Das S; Shinde SV; Sinha S; Somasundaram K; Samuelson AG
Chemistry; 2012 Sep; 18(39):12278-91. PubMed ID: 22903299
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of interstrand migration of organoruthenium anticancer complexes within a DNA duplex.
Wu K; Luo Q; Hu W; Li X; Wang F; Xiong S; Sadler PJ
Metallomics; 2012 Feb; 4(2):139-48. PubMed ID: 22262368
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxicity of half sandwich ruthenium(II) complexes with strong hydrogen bond acceptor ligands and their mechanism of action.
Das S; Sinha S; Britto R; Somasundaram K; Samuelson AG
J Inorg Biochem; 2010 Feb; 104(2):93-104. PubMed ID: 19913918
[TBL] [Abstract][Full Text] [Related]
24. Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity.
Auzias M; Therrien B; Süss-Fink G; Stepnicka P; Ang WH; Dyson PJ
Inorg Chem; 2008 Jan; 47(2):578-83. PubMed ID: 18085776
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, DNA-binding, photocleavage, cytotoxicity and antioxidant activity of ruthenium (II) polypyridyl complexes.
Liu YJ; Zeng CH; Huang HL; He LX; Wu FH
Eur J Med Chem; 2010 Feb; 45(2):564-71. PubMed ID: 19932529
[TBL] [Abstract][Full Text] [Related]
26. Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells.
Guo W; Zheng W; Luo Q; Li X; Zhao Y; Xiong S; Wang F
Inorg Chem; 2013 May; 52(9):5328-38. PubMed ID: 23586415
[TBL] [Abstract][Full Text] [Related]
27. Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: detection of a sulfenato intermediate.
Wang F; Xu J; Habtemariam A; Bella J; Sadler PJ
J Am Chem Soc; 2005 Dec; 127(50):17734-43. PubMed ID: 16351102
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, antitumor activity and structure-activity relationships of a series of Ru(II) complexes.
Liu J; Zheng W; Shi S; Tan C; Chen J; Zheng K; Ji L
J Inorg Biochem; 2008 Feb; 102(2):193-202. PubMed ID: 17825915
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of ruthenium(II) complexes and characterization of their cytotoxicity in vitro, apoptosis, DNA-binding and antioxidant activity.
Liu YJ; Zeng CH; Liang ZH; Yao JH; Huang HL; Li ZZ; Wu FH
Eur J Med Chem; 2010 Jul; 45(7):3087-95. PubMed ID: 20417586
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, structure, DNA-binding properties, and cytotoxicity of ruthenium(II) polypyridyl complexes.
Liu YJ; Zeng CH; Yao JH; Wu FH; He LX; Huang HL
Chem Biodivers; 2010 Jul; 7(7):1770-83. PubMed ID: 20658665
[TBL] [Abstract][Full Text] [Related]
31. New π-arene ruthenium(II) piano-stool complexes with nitrogen ligands.
Grau J; Noe V; Ciudad C; Prieto MJ; Font-Bardia M; Calvet T; Moreno V
J Inorg Biochem; 2012 Apr; 109():72-81. PubMed ID: 22387934
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxicity, apoptosis, cellular uptake, cell cycle arrest, photocleavage, and antioxidant activity of 1, 10-phenanthroline ruthenium(II) complexes.
Liu YJ; Li ZZ; Liang ZH; Yao JH; Huang HL
DNA Cell Biol; 2011 Oct; 30(10):839-48. PubMed ID: 21568758
[TBL] [Abstract][Full Text] [Related]
33. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
34. Dinuclear ruthenium(II) triple-stranded helicates: luminescent supramolecular cylinders that bind and coil DNA and exhibit activity against cancer cell lines.
Pascu GI; Hotze AC; Sanchez-Cano C; Kariuki BM; Hannon MJ
Angew Chem Int Ed Engl; 2007; 46(23):4374-8. PubMed ID: 17477461
[No Abstract] [Full Text] [Related]
35. Interaction of rac-[Ru(5,6-dmp)3]2+ with DNA: enantiospecific DNA binding and ligand-promoted exciton coupling.
Maheswari PU; Rajendiran V; Stoeckli-Evans H; Palaniandavar M
Inorg Chem; 2006 Jan; 45(1):37-50. PubMed ID: 16390038
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
37. Differences in the cellular response and signaling pathways between cisplatin and monodentate organometallic Ru(II) antitumor complexes containing a terphenyl ligand.
Kisova A; Zerzankova L; Habtemariam A; Sadler PJ; Brabec V; Kasparkova J
Mol Pharm; 2011 Jun; 8(3):949-57. PubMed ID: 21480648
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, DNA-binding and topoisomerase inhibitory activity of ruthenium(II) polypyridyl complexes.
Du KJ; Wang JQ; Kou JF; Li GY; Wang LL; Chao H; Ji LN
Eur J Med Chem; 2011 Apr; 46(4):1056-65. PubMed ID: 21295892
[TBL] [Abstract][Full Text] [Related]
39. Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms.
Vock CA; Ang WH; Scolaro C; Phillips AD; Lagopoulos L; Juillerat-Jeanneret L; Sava G; Scopelliti R; Dyson PJ
J Med Chem; 2007 May; 50(9):2166-75. PubMed ID: 17419606
[TBL] [Abstract][Full Text] [Related]
40. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
